HIV/AIDS Press Release
|06/04/2020 - 07:22||
Mylan and Lupin Receive European Marketing Authorization for Nepexto, Biosimilar Etanercept
HERTFORDSHIRE, England , PITTSBURGH and MUMBAI, India , June 4, 2020 / / -- Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Nepexto ® , a biosimilar to Enbrel ® (etanercept), for all indications of the reference product including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis.
|06/03/2020 - 15:23||
UC awards $2 million in critical research seed funding for COVID-19 high-risk populations
The University of California today (June 3) announced the distribution of $2 million in seed funding for important research across the state aimed at mitigating the impact of COVID-19, particularly among those at greater risk for infection and adverse outcomes. UC awarded the funds to support rapid-response, high-impact research in vaccines, therapeutics, clinical management, epidemiology and other COVID-19 related areas. In addition to UC campuses, other institutions of higher education as well as private and nonprofit groups in California received awards.
|University of C...|
|05/31/2020 - 18:57||
Federal judge enters order of permanent injunction against New York company for distributing unapproved drugs
A federal judge has ordered two individuals doing business as Sundial Herbal Products to stop distributing unapproved new drugs and misbranded drugs until they comply with federal law. According to the complaint, despite previous warnings from the U.S. Food and Drug Administration and repeated promises to correct violations, Sundial continued to violate the law and distribute their products.
|05/29/2020 - 13:04||
Mylan Invalidates Sanofi's Lantus SoloSTAR Device Patents in IPR Proceedings
HERTFORDSHIRE, England and PITTSBURGH , May 29, 2020 / / -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus® SoloSTAR® device patents, U.S. Patent Nos.
|05/27/2020 - 11:50||
Cone Health Part of Long-Lasting HIV Prevention Trial
While not a vaccine, a long-acting medication given every two months provided high-level protection against HIV in high-risk populations. (Men who have sex with men and transgender women.) Long-acting injections of cabotegravir proved not only to be just as good as the highly effective daily oral HIV prevention medication Truvada, the drug showed a trend towards superiority.
|05/19/2020 - 17:01||
We Roar: A COVID vaccine in 12-18 months? Dont count on it
Dr. Gordon Douglas, a Class of 1955 alumnus, has decades of experience looking at vaccines from all sides: as a practicing physician, as a professor in medical schools, as a medical investigator, as the president of Merck?s vaccine division , in his work with start-up companies developing new drugs and vaccines, and in his efforts to distribute tuberculosis vaccines to developing nations.
|05/18/2020 - 13:07||
Trial Finds Long-Acting Injectable Antiviral Safe and Effective HIV Prevention for Some Populations
AVAC calls for trial among women to continue with urgency and to accelerate planning for possible introduction of new option to prevent HIV
|AIDS Vaccine Ad...|
|05/18/2020 - 11:41||
SELLAS Establishes Independent Data Monitoring Committee of Leading Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial
Independent Data Monitoring Committee (DMC) to Review and Evaluate Patient Safety and Efficacy Data for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second Remission Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center to serve as DMC Chair Thomas Fleming, Ph.
|SELLAS Life Sciences|
|05/18/2020 - 01:43||
Global HIV prevention study to stop early after ViiV Healthcares long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
Interim analysis from HPTN 083 study shows investigational, long-acting injectable cabotegravir (CAB LA) administered every two months is 69% more effective than daily pills in preventing HIV acquisition Participants who were in the daily oral emtricitabine/tenofovir disoproxil fumarate 200 mg and 300 mg (FTC/TDF) tablet arm of the study will be offered CAB LA
|05/14/2020 - 04:08||
New Bipartisan Letter to Congress on Urgency for International COVID-19 Response
Dear Speaker Pelosi, Minority Leader McCarthy, Majority Leader McConnell, and Minority Leader Schumer:
|05/13/2020 - 19:40||
Health Heroes Act Addresses Critical COVID-19 Needs, Should be Strengthened
H.R.6800, the Health Heroes Act, includes policies and investments that would bolster the federal response to COVID-19, increase testing capacity and availability of medical supplies and address the disparate impact of COVID-19 on vulnerable populations. The House of Representatives is weighing provisions in the bill, and is expected to negotiate with the Senate in the coming weeks.
|05/13/2020 - 16:35||
Yale researchers discover how HIV hides from treatment
Even after successful antiretroviral therapy, HIV can hide dormant in a tiny number of immune system cells for decades and re-emerge to threaten the life of its host. Now Yale University researchers have discovered a molecular explanation for how the virus accomplishes this insidious trick, they report May 13 in the journal Science Translational Medicine.
|05/12/2020 - 20:15||
Learn more about Gladstone's COVID-19 research projects and how science will overcome this pandemic.
In response to the COVID-19 pandemic, Gladstone scientists have rapidly pivoted the focus of their research labs to the novel virus, SARS-CoV-2.
|05/12/2020 - 15:58||
Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19
HERTFORDSHIRE, England and PITTSBURGH, May 12, 2020 / / -- Mylan N.V. (NASDAQ: MYL) today announced, as part of its ongoing efforts to support patients and public health needs during the COVID-19 pandemic, a global collaboration with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19.
|05/12/2020 - 06:38||
Moving from speculation to science during a pandemic
Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.
|05/12/2020 - 00:44||
COVID-19 Crisis: Pelosi and McConnell Must Embrace New Research Deal
PETA Urges Congressional Leaders to Recognize 'Research Modernization Deal' As Animal Experiments Fail to Provide Treatments, Vaccines.
|05/11/2020 - 21:06||
House Democrats Introduce The Heroes Act: A New Legislative Package to Respond to COVID-19 Pandemic
On May 12, House Democrats introduced H.R. 6800, the Heroes Act, a $3 trillion dollar legislative package to address the COVID-19 pandemic. The legislation includes a number of provisions designed to maintain and increase access to mental health and substance use disorder treatment services:
|05/11/2020 - 17:46||
Fred Hutch and the Seattle Cancer Care Alliance awarded Bank of America grant for COVID-19 relief efforts
Scanning electron microscope image of SARS-CoV-2, isolated from a patient, emerging from the surface of cells cultured in the lab. Image captured and color-enhanced by National Institute of Allergy and Infectious Diseases National Institute of Allergy and Infectious Diseases.
|05/11/2020 - 11:49||
The cost of inaction: COVID-19-related service disruptions could cause hundreds of thousands of extra deaths from HIV
Gains made in preventing mother-to-child transmission of HIV could be reversed, with new HIV infections among children up by as much as 104%
|05/11/2020 - 11:12||
Fred Hutch, NIH experts outline plan for COVID-19 vaccines
In a Science perspective, experts urge multi-pronged, coordinated approach to successfully develop COVID-19 vaccines.
|05/08/2020 - 15:39||
Roddenberry Foundation Donates $1 Million to Support Gladstone COVID-19 Research
Developing a state-of-the-art diagnostic device using novel CRISPR technology, blocking the entrance of coronavirus into human cells, identifying existing FDA-approved drugs as treatments, and creating a research hub to support the study of live coronavirus—these are just a few of the projects that Gladstone scientists have pivoted to in order to end the COVID-19 pandemic.
|05/08/2020 - 10:45||
Virginia Mason Begins Reopening Outpatient Services for In-Person Visits
Bainbridge Island Regional Medical Center (shown here) is one of eight locations where Virginia Mason provides outpatient services. There others are the main Virginia Mason campus on First Hill in Seattle; Bellevue; Edmonds; Federal Way; Issaquah; Kirkland; Lynnwood; and University Village near the University of Washington campus.
|Virginia Mason ...|
|05/07/2020 - 17:14||
Two New Research Institutes in the Bay Area
Gladstone Institutes is launching two new biomedical research institutes to broaden its impact on unsolved diseases. The first is the Gladstone Institute of Virology, led by Melanie Ott, MD, PhD, which will study the current coronavirus, as well as search for novel therapies against future infectious diseases. The second is the result of a close partnership with UC San Francisco (UCSF); the Gladstone-UCSF Institute of Genomic Immunology, led by Alexander Marson, MD, PhD, will bring together genomics and immunology to develop next-generation cell therapies.
|05/07/2020 - 09:57||
Virginia Mason Helps Lead National Clinical Trial to Accelerate Exploration, Approval of New Pancreatic Cancer Therapies
SEATTLE – (May 7, 2020) – Virginia Mason has joined 14 other medical institutions and cancer research centers across the nation in activating Precision Promise, the Pancreatic Cancer Action Network’s (PanCAN) innovative adaptive clinical trial designed to accelerate exploration and approval of new treatment options.
|Virginia Mason ...|
|05/06/2020 - 18:14||
People from around the world donate money and equipment to accelerate science at Gladstone
Fall cohort of five new Gladstone Foundation Board members brings expertise from biotech, venture capital, asset management, and real estate industries.